{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:08:30Z","timestamp":1790651310337,"version":"4.1.0"},"reference-count":94,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","bmn.com","cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Molecular Medicine"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.molmed.2024.05.001","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T20:12:31Z","timestamp":1717099951000},"page":"765-780","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Immunomodulatory drugs: a promising clinical ally for cancer immunotherapy"],"prefix":"10.1016","volume":"30","author":[{"given":"Abigail","family":"Colley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Brauns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann E.","family":"Sluder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C.","family":"Poznansky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2200-2029","authenticated-orcid":false,"given":"Yohannes","family":"Gemechu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmed.2024.05.001_bb0005","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.molmed.2017.02.006","article-title":"A brighter side to thalidomide: its potential use in immunological disorders","volume":"23","author":"Millrine","year":"2017","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.molmed.2024.05.001_bb0010","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/bdrc.21096","article-title":"Thalidomide-induced teratogenesis: history and mechanisms","volume":"105","author":"Vargesson","year":"2015","journal-title":"Birth Defects Res. C"},{"key":"10.1016\/j.molmed.2024.05.001_bb0015","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","article-title":"Thalidomide is an inhibitor of angiogenesis","volume":"91","author":"D\u2019Amato","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2024.05.001_bb0020","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1038\/leu.2012.119","article-title":"Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide","volume":"26","author":"Lopez-Girona","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.molmed.2024.05.001_bb0025","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity","volume":"327","author":"Ito","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.molmed.2024.05.001_bb0030","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nature13527","article-title":"Structure of the DDB1\u2013CRBN E3 ubiquitin ligase in complex with thalidomide","volume":"512","author":"Fischer","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2024.05.001_bb0035","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nsmb.2874","article-title":"Structure of the human Cereblon\u2013DDB1\u2013lenalidomide complex reveals basis for responsiveness to thalidomide analogs","volume":"21","author":"Chamberlain","year":"2014","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.molmed.2024.05.001_bb0040","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kr\u00f6nke","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.molmed.2024.05.001_bb0045","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nature14610","article-title":"Lenalidomide induces ubiquitination and degradation of CK1\u03b1 in del(5q) MDS","volume":"523","author":"Kr\u00f6nke","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2024.05.001_bb0050","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/s41589-018-0129-x","article-title":"SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate","volume":"14","author":"Matyskiela","year":"2018","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.molmed.2024.05.001_bb0055","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15398","article-title":"pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4CRBN ubiquitin ligase","volume":"8","author":"An","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2024.05.001_bb0060","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nature18611","article-title":"A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase","volume":"535","author":"Matyskiela","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2024.05.001_bb0065","doi-asserted-by":"crossref","first-page":"940","DOI":"10.3389\/fimmu.2020.00940","article-title":"The tumor microenvironment: a milieu hindering and obstructing antitumor immune responses","volume":"11","author":"Labani-Motlagh","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2024.05.001_bb0070","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1182\/blood.V98.1.210","article-title":"Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma","volume":"98","author":"Davies","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2024.05.001_bb0075","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1365-2141.2004.05286.x","article-title":"Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application","volume":"128","author":"Hayashi","year":"2005","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.molmed.2024.05.001_bb0080","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1084\/jem.187.11.1885","article-title":"Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8\u03e9 subset","volume":"187","author":"Haslett","year":"1998","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.molmed.2024.05.001_bb0085","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1182\/blood-2003-02-0361","article-title":"Immunomodulatory drug costimulates T cells via the B7-CD28 pathway","volume":"103","author":"LeBlanc","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2024.05.001_bb0090","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00262-012-1308-3","article-title":"Lenalidomide enhances anti-myeloma cellular immunity","volume":"62","author":"Luptakova","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.molmed.2024.05.001_bb0095","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.12708","article-title":"Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors I karos and A iolos via modulation of the E 3 ubiquitin ligase complex CRL 4 CRBN","volume":"164","author":"Gandhi","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.molmed.2024.05.001_bb0100","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.3390\/ijms24043136","article-title":"Monoclonal antibodies: the greatest resource to treat multiple myeloma","volume":"24","author":"De Luca","year":"2023","journal-title":"IJMS"},{"key":"10.1016\/j.molmed.2024.05.001_bb0105","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3324\/haematol.2010.030759","article-title":"Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab","volume":"96","author":"Van Der Veer","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.molmed.2024.05.001_bb0110","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.3324\/haematol.2017.178947","article-title":"Expression of programmed death-1 on lymphocytes in myeloma patients is lowered during lenalidomide maintenance","volume":"103","author":"Danhof","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.molmed.2024.05.001_bb0115","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/s41375-020-0809-x","article-title":"Immunomodulatory drugs activate NK cells via both Zap-70 and cereblon-dependent pathways","volume":"35","author":"Hideshima","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.molmed.2024.05.001_bb0120","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00262-014-1610-3","article-title":"Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-\u03b1 pathways","volume":"64","author":"Balasa","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.molmed.2024.05.001_bb0125","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1200\/JCO.21.02815","article-title":"Elotuzumab plus pomalidomide and dexamethasone for relapsed\/refractory multiple myeloma: final overall survival analysis from the randomized Phase II ELOQUENT-3 trial","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.molmed.2024.05.001_bb0130","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41408-020-00357-4","article-title":"Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study","volume":"10","author":"Dimopoulos","year":"2020","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.molmed.2024.05.001_bb0135","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1016\/S2352-3026(19)30109-7","article-title":"Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial","volume":"6","author":"Usmani","year":"2019","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.molmed.2024.05.001_bb0140","doi-asserted-by":"crossref","first-page":"e459","DOI":"10.1016\/S2352-3026(19)30110-3","article-title":"Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial","volume":"6","author":"Mateos","year":"2019","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.molmed.2024.05.001_bb0145","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1158\/2326-6066.CIR-19-0148","article-title":"Lessons learned from checkpoint blockade targeting PD-1 in multiple myeloma","volume":"7","author":"Lesokhin","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.molmed.2024.05.001_bb0150","doi-asserted-by":"crossref","first-page":"5984","DOI":"10.1158\/1078-0432.CCR-05-0577","article-title":"Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model","volume":"11","author":"Hernandez-Ilizaliturri","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molmed.2024.05.001_bb0155","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1158\/1078-0432.CCR-07-4405","article-title":"Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells","volume":"14","author":"Wu","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molmed.2024.05.001_bb0160","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s40273-020-00971-x","article-title":"Lenalidomide with rituximab for previously treated follicular lymphoma and marginal zone lymphoma: an evidence review group perspective of a NICE single technology appraisal","volume":"39","author":"Witlox","year":"2021","journal-title":"PharmacoEconomics"},{"key":"10.1016\/j.molmed.2024.05.001_bb0165","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: a Phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"JCO"},{"key":"10.1016\/j.molmed.2024.05.001_bb0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0080437","article-title":"Immunomodulatory effects in a Phase II study of lenalidomide combined with cetuximab in refractory KRAS-mutant metastatic colorectal cancer patients","volume":"8","author":"Gandhi","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.molmed.2024.05.001_bb0175","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1007\/s00280-016-3000-3","article-title":"Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer","volume":"77","author":"Said","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.molmed.2024.05.001_bb0180","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/nm.4128","article-title":"Immunomodulatory drugs disrupt the cereblon\u2013CD147\u2013MCT1 axis to exert antitumor activity and teratogenicity","volume":"22","author":"Eichner","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2024.05.001_bb0185","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1182\/blood-2009-04-217687","article-title":"Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy","volume":"114","author":"Ramsay","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2024.05.001_bb0190","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1038\/leu.2016.84","article-title":"Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade","volume":"30","author":"Suen","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.molmed.2024.05.001_bb0195","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1007\/s00262-019-02411-y","article-title":"Lenalidomide improves the therapeutic effect of an interferon-\u03b1-dendritic cell-based lymphoma vaccine","volume":"68","author":"Lapenta","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.molmed.2024.05.001_bb0200","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1158\/1078-0432.CCR-11-1221","article-title":"Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses","volume":"18","author":"Noonan","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molmed.2024.05.001_bb0205","doi-asserted-by":"crossref","first-page":"27252","DOI":"10.18632\/oncotarget.15917","article-title":"Combination therapy with dendritic cells and lenalidomide is an effective approach to enhance antitumor immunity in a mouse colon cancer model","volume":"8","author":"Vo","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.molmed.2024.05.001_bb0210","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3390\/vaccines9050509","article-title":"Stay on target: reengaging cancer vaccines in combination immunotherapy","volume":"9","author":"Wolfson","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.molmed.2024.05.001_bb0215","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1016\/j.urolonc.2012.05.007","article-title":"Lenalidomide augments the efficacy of bacillus Calmette-Guerin (BCG) immunotherapy in vivo","volume":"31","author":"Jinesh","year":"2013","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.molmed.2024.05.001_bb0220","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.3267","article-title":"Assessment of safety and immunogenicity of PVX-410 vaccine with or without lenalidomide in patients with smoldering multiple myeloma: a nonrandomized clinical trial","volume":"4","author":"Nooka","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.molmed.2024.05.001_bb0225","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1182\/asheducation-2016.1.521","article-title":"Cellular and vaccine immunotherapy for multiple myeloma","volume":"2016","author":"Garfall","year":"2016","journal-title":"Hematology"},{"key":"10.1016\/j.molmed.2024.05.001_bb0230","doi-asserted-by":"crossref","first-page":"6696","DOI":"10.1158\/1078-0432.CCR-21-1916","article-title":"An allogeneic multiple myeloma GM-CSF-secreting vaccine with lenalidomide induces long-term immunity and durable clinical responses in patients in near complete remission","volume":"27","author":"Biavati","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molmed.2024.05.001_bb0235","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS7586","article-title":"A novel microbial-derived peptide therapeutic vaccine (EO2463) as monotherapy and in combination with lenalidomide and rituximab, for treatment of patients with indolent non-Hodgkin lymphoma (SIDNEY)","volume":"40","author":"Zinzani","year":"2022","journal-title":"JCO"},{"key":"10.1016\/j.molmed.2024.05.001_bb0240","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.molimm.2005.03.007","article-title":"Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells","volume":"43","author":"Offner","year":"2006","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.molmed.2024.05.001_bb0245","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.imbio.2008.11.014","article-title":"Mode of cytotoxic action of T cell-engaging BiTE antibody MT110","volume":"214","author":"Haas","year":"2009","journal-title":"Immunobiology"},{"key":"10.1016\/j.molmed.2024.05.001_bb0250","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1182\/bloodadvances.2020002524","article-title":"The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models","volume":"4","author":"Cho","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.molmed.2024.05.001_bb0255","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/bloodadvances.2020003805","article-title":"Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma","volume":"5","author":"Verkleij","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.molmed.2024.05.001_bb0260","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1158\/2643-3230.BCD-21-0028","article-title":"Bispecific antibodies in multiple myeloma: present and future","volume":"2","author":"Lancman","year":"2021","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.molmed.2024.05.001_bb0265","doi-asserted-by":"crossref","first-page":"7289","DOI":"10.1182\/blood-2022-159756","article-title":"MajesTEC-4 (EMN30): a Phase 3 trial of teclistamab + lenalidomide versus lenalidomide alone as maintenance therapy following autologous stem cell transplantation in patients with newly diagnosed multiple myeloma","volume":"140","author":"Zamagni","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2024.05.001_bb0270","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s13402-023-00833-6","article-title":"Lenalidomide overcomes the resistance to third-generation CD19-CAR-T cell therapy in preclinical models of diffuse large B-cell lymphoma","volume":"46","author":"Jin","year":"2023","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.molmed.2024.05.001_bb0275","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1115940","article-title":"Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells","volume":"5","author":"Ot\u00e1hal","year":"2016","journal-title":"OncoImmunology"},{"key":"10.1016\/j.molmed.2024.05.001_bb0280","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1158\/1078-0432.CCR-17-0344","article-title":"Lenalidomide enhances the function of CS1 chimeric antigen receptor-redirected T cells against multiple myeloma","volume":"24","author":"Wang","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molmed.2024.05.001_bb0285","doi-asserted-by":"crossref","DOI":"10.1177\/0963689720920825","article-title":"Lenalidomide enhances CAR-T cell activity against solid tumor cells","volume":"29","author":"Wang","year":"2020","journal-title":"Cell Transplant."},{"key":"10.1016\/j.molmed.2024.05.001_bb0290","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1158\/1535-7163.MCT-18-1146","article-title":"Anti-B-cell maturation antigen chimeric antigen receptor T cell function against multiple myeloma is enhanced in the presence of lenalidomide","volume":"18","author":"Works","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.molmed.2024.05.001_bb0295","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00262-021-02959-8","article-title":"Lenalidomide enhances the efficacy of anti-BCMA CAR-T treatment in relapsed\/refractory multiple myeloma: a case report and revies of the literature","volume":"71","author":"Zhao","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.molmed.2024.05.001_bb0300","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2024.05.001_bb0305","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.2022015526","article-title":"Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents","volume":"141","author":"Cohen","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2024.05.001_bb0310","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1080\/10428194.2022.2043299","article-title":"Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia","volume":"63","author":"Tettamanti","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.molmed.2024.05.001_bb0315","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1182\/blood-2021-151109","article-title":"Lenalidomide exposure at time of CAR T-cells expansion enhances response of refractory\/relapsed aggressive large B-cell lymphomas","volume":"138","author":"Lemoine","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2024.05.001_bb0320","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/blood-2020-136279","article-title":"Lenalidomide enhance CAR T-cells response in patients with refractory\/relapsed large B cell lymphoma experiencing progression after infusion","volume":"136","author":"Thieblemont","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2024.05.001_bb0325","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1080\/16078454.2021.1981534","article-title":"Lenalidomide improves the antitumor activity of CAR-T cells directed toward the intracellular Wilms Tumor 1 antigen","volume":"26","author":"Zhang","year":"2021","journal-title":"Hematology"},{"key":"10.1016\/j.molmed.2024.05.001_bb0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e20460","article-title":"Lenalidomide improves NKG2D-based CAR-T cell activity against colorectal cancer cells invitro","volume":"9","author":"Zarei","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.molmed.2024.05.001_bb0335","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1002\/cncr.22290","article-title":"Phase II study of lenalidomide in patients with metastatic renal cell carcinoma","volume":"107","author":"Choueiri","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.molmed.2024.05.001_bb0340","doi-asserted-by":"crossref","first-page":"5269","DOI":"10.1158\/1078-0432.CCR-10-1928","article-title":"Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a Phase I\/II double-blinded, randomized study","volume":"16","author":"Keizman","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molmed.2024.05.001_bb0345","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s10637-007-9107-y","article-title":"Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma","volume":"26","author":"Patel","year":"2008","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.molmed.2024.05.001_bb0350","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1200\/JCO.2010.31.3601","article-title":"Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium Study PBTC-018","volume":"29","author":"Warren","year":"2011","journal-title":"JCO"},{"key":"10.1016\/j.molmed.2024.05.001_bb0355","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/cncr.24686","article-title":"Results of a multicenter, randomized, double-blind phase 2\/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma","volume":"116","author":"Eisen","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.molmed.2024.05.001_bb0360","doi-asserted-by":"crossref","first-page":"5228","DOI":"10.1002\/cncr.24576","article-title":"Results of a multicenter, randomized, double-blind, dose-evaluating phase 2\/3 study of lenalidomide in the treatment of metastatic malignant melanoma","volume":"115","author":"Glaspy","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.molmed.2024.05.001_bb0365","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.3390\/cells11223626","article-title":"Tumor microenvironment immunosuppression: a roadblock to CAR T-cell advancement in solid tumors","volume":"11","author":"Cheever","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.molmed.2024.05.001_bb0370","doi-asserted-by":"crossref","first-page":"8572","DOI":"10.3390\/ijms22168572","article-title":"Immunomodulatory drugs for the treatment of B cell malignancies","volume":"22","author":"Ioannou","year":"2021","journal-title":"IJMS"},{"key":"10.1016\/j.molmed.2024.05.001_bb0375","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.omto.2020.06.013","article-title":"A Cereblon modulator CC-885 induces CRBN- and p97-dependent PLK1 degradation and synergizes with volasertib to suppress lung cancer","volume":"18","author":"Li","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.molmed.2024.05.001_bb0380","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-2141.2011.08689.x","article-title":"Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response","volume":"154","author":"Lopez-Girona","year":"2011","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.molmed.2024.05.001_bb0385","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1084\/jem.177.6.1675","article-title":"Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation","volume":"177","author":"Moreira","year":"1993","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.molmed.2024.05.001_bb0390","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1084\/jem.173.3.699","article-title":"Thalidomide selectively inhibits tumor necrosis factor ac production by stimulated human monocytes","volume":"173","author":"Sampaio","year":"1991","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.molmed.2024.05.001_bb0395","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/intimm\/dxw005","article-title":"Immunomodulatory drugs inhibit TLR4-induced type-1 interferon production independently of Cereblon via suppression of the TRIF\/IRF3 pathway","volume":"28","author":"Millrine","year":"2016","journal-title":"Int. Immunol."},{"key":"10.1016\/j.molmed.2024.05.001_bb0400","article-title":"Tumor and microenvironmental mechanisms of resistance to immunomodulatory drugs in multiple myeloma","volume":"12","author":"Chen","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.molmed.2024.05.001_bb0405","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1038\/s41375-018-0040-1","article-title":"Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network","volume":"32","author":"Ludwig","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.molmed.2024.05.001_bb0410","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1021\/acs.jmedchem.0c01489","article-title":"CC-90009: a Cereblon E3 ligase modulating drug that promotes selective degradation of GSPT1 for the treatment of acute myeloid leukemia","volume":"64","author":"Hansen","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.molmed.2024.05.001_bb0415","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1182\/blood.2020008676","article-title":"CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells","volume":"137","author":"Surka","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2024.05.001_bb0420","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/s41375-019-0620-8","article-title":"Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN","volume":"34","author":"Bjorklund","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.molmed.2024.05.001_bb0425","doi-asserted-by":"crossref","first-page":"11802","DOI":"10.1073\/pnas.1814446115","article-title":"Humanized cereblon mice revealed two distinct therapeutic pathways of immunomodulatory drugs","volume":"115","author":"Gemechu","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2024.05.001_bb0430","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1182\/blood-2018-05-852798","article-title":"Crbn I391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice","volume":"132","author":"Fink","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2024.05.001_bb0435","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1038\/onc.2010.611","article-title":"Activation of nuclear factor-kappa B signalling promotes cellular senescence","volume":"30","author":"Rovillain","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.molmed.2024.05.001_bb0440","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12979-022-00277-w","article-title":"NF-\u03baB, a culprit of both inflamm-ageing and declining immunity?","volume":"19","author":"Songkiatisak","year":"2022","journal-title":"Immun. Ageing"},{"key":"10.1016\/j.molmed.2024.05.001_bb0445","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1182\/blood-2007-10-117457","article-title":"Thalidomide for treatment of multiple myeloma: 10 years later","volume":"111","author":"Palumbo","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2024.05.001_bb0450","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2024.05.001_bb0455","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1182\/blood-2011-01-330126","article-title":"A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-\/Intermediate-1-risk myelodysplastic syndromes with del5q","volume":"118","author":"Fenaux","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2024.05.001_bb0460","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","article-title":"Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: Phase II MCL-001 (EMERGE) study","volume":"31","author":"Goy","year":"2013","journal-title":"JCO"},{"key":"10.1016\/j.molmed.2024.05.001_bb0465","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"14","author":"Miguel","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.molmed.2024.05.001_bb0470","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.1200\/JCO.2016.69.3812","article-title":"Pomalidomide for symptomatic Kaposi\u2019s sarcoma in people with and without HIV infection: a Phase I\/II study","volume":"34","author":"Polizzotto","year":"2016","journal-title":"JCO"}],"container-title":["Trends in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491424001230?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491424001230?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T15:12:55Z","timestamp":1723648375000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471491424001230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":94,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S1471491424001230"],"URL":"https:\/\/doi.org\/10.1016\/j.molmed.2024.05.001","relation":{},"ISSN":["1471-4914"],"issn-type":[{"value":"1471-4914","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunomodulatory drugs: a promising clinical ally for cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Trends in Molecular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmed.2024.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}